Agile Therapeutics Inc Overview
Pro stress-test →Agile Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of prescription contraceptive products for women. The company was acquired by Insud Pharma, S.L. in August 2024 for an enterprise value of approximately $45 million, with shareholders receiving $1.52 per share in cash.
Strategic Profile
Pro stress-test →The company's lead product candidate is Twirla, a once-weekly contraceptive patch. Following the acquisition, Agile combined with Insud Pharma's US subsidiary, Exeltis USA, Inc., expanding their women's health and contraceptive portfolio. Agile now operates as an indirect subsidiary of Insud and has ceased to be listed on any public market.
Competitive Landscape
Pro stress-test →Agile competed in the women's hormonal contraceptive market against established oral contraceptive brands (e.g., Yaz, Ortho-Cyclen) and other contraceptive delivery methods. The company's Twirla patch technology differentiated on convenience (once-weekly dosing) compared to daily oral pills, positioning against products like Xulane (norelgestromin/ethinyl estradiol) from Allergan. However, limited market penetration and inability to sustain independent operations led to acquisition.
Industry Context
Agile Therapeutics Inc operates in Pharmaceutical Manufacturing & Development (Women's Health).
Key facts
Headquarters: Princeton, US